symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
SVRA,3.49,0.787763,492432,471753742,0,1.08-4.21,-0.02,Savara Inc.,USD,0001160308,US8051111016,805111101,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.savarapharma.com,"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.","Mr. Matthew  Pauls J.D., M.B.A.",Healthcare,US,28,512 614 1848,Building III,Austin,TX,78746,0.74653,2.00347,https://financialmodelingprep.com/image-stock/SVRA.png,2017-04-28,False,False,True,False,False
